Innovative Diagnostic Technology Singulex's Single Molecule Counting technology offers up to 1000 times greater sensitivity than traditional immunoassays, enabling more precise biomarker detection. This cutting-edge technology opens opportunities to partner with laboratories and healthcare providers seeking highly sensitive diagnostic solutions for early disease detection and clinical research.

Expanding Market Presence With the commercialization of the Clarity system in Europe and ongoing development of infectious and inflammatory disease assays, there is significant potential to expand sales in global markets. Collaborating with healthcare distributors and clinical laboratories can accelerate adoption of Singulex’s platform and assays across diverse regions.

Strategic Partnerships Singulex’s collaborations with industry leaders such as QIAGEN and Grifols indicate a strong pathway to develop companion diagnostics and plasma-based testing solutions. Building on these relationships could lead to co-marketing opportunities, access to new customer segments, and increased product integration in clinical workflows.

Recent Funding Growth Securing $50 million in senior-secured debt demonstrates investor confidence and provides capital to fund product expansion and new assay development. Engaging with potential clients on the basis of financial stability and innovation can position Singulex as a trustworthy partner for advanced diagnostic solutions.

Product Launch & Commercialization The launch of the Clarity C. difficile toxin assay presents opportunities to target infectious disease testing markets. Focused outreach to infectious disease laboratories, hospitals, and health systems can drive adoption of these high-sensitivity assays, expanding Singulex’s footprint in point-of-care and clinical diagnostics sectors.